Druggability & Clinical Context
Druggability
Low
Score: 0.35
Target Class
Transcription Factor
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
11
Known Drugs:
2
Approved:
2
In Clinical Trials:
0
Drug Pipeline (2 compounds)
2 Approved
Therapeutic Areas:Neuroinflammation Neurodegenerative diseases (Alzheimer's, Parkinson's, MS) Autoimmune disorders Regulatory T cell (Treg) immunotherapy Cancer immunotherapy (checkpoint combination strategies)
Druggability Rationale: FOXP3 presents significant druggability challenges as a transcription factor lacking established small molecule binding pockets, reflected in its low druggability score of 0.30. Current approved approaches (IL-2, Rapamycin) work indirectly through upstream signaling rather than direct target engagement, suggesting that future strategies may require innovative modalities such as protein-protein interaction inhibitors, peptide therapeutics, or epigenetic modulation rather than conventional small molecule development.
Mechanism: Transcription factor modulation - no direct small molecule binding
Drug Pipeline (2 compounds)
2 Approved
Known Drugs:Low-dose IL-2 (approved) — Treg expansion, indirectly upregulates FOXP3
Rapamycin (approved) — mTOR inhibitor, promotes FOXP3+ Treg differentiation
Structural Data:PDB (11) ✓AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:FOXP3 contains a conserved forkhead DNA-binding domain (resolved in multiple PDB structures including 3QRF at 2.8 Å resolution) that recognizes specific DNA sequences, but lacks a defined allosteric small molecule binding pocket. Structural data suggests potential druggability through protein-protein interaction interfaces (e.g., with RUNX1, TIP60) rather than orthosteric binding, making this target more amenable to biologics or protein degradation approaches.
Selectivity & Safety Considerations
FOXP3 selectivity is complicated by its role as a master transcription factor with broad downstream effects on immune tolerance, raising risks of systemic immunosuppression with direct modulation. The target has limited isoform diversity, but off-target engagement through indirect mechanisms (mTOR, IL-2 signaling) remains a significant concern for achieving therapeutic selectivity without dampening protective immune responses.
Clinical Trials (2)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 1 · PHASE2: 1
PHASE2
NCT03776643
n=24
Allergic Rhinoconjunctivitis to Birch Po, With a Positive Skin Prick Test to Birch
Interventions: ILT-101 ld-(IL2)
Sponsor: Assistance Publique - Hôpitaux de Paris | Started: 2019-02-01
NA
NCT01681381
n=2790
Ischemic Heart Disease, Myocardial Ischemia, Coronary Artery Lesions,Primary
Interventions: Tivoli® DES, Firebird2® DES
Sponsor: Essen Technology (Beijing) Co., Ltd. | Started: 2012-09